LPCN Stock Analysis: Buy, Sell, or Hold?
LPCN - Lipocine Inc.
$2.53
0.24 (10.48%)
▲
5d:
+10.48%
30d:
+13.96%
90d:
-65.39%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When LPCN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: LPCN is 8.1% above its trading range ($2.34). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: LPCN is 8.1% above its trading range ($2.34). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: LPCN is currently trading at $2.53, which is considered extended relative to its 30-day fair value range of $2.12 to $2.34.
Technical Outlook: Technically, LPCN is in a strong downtrend. The price is approaching resistance at $2.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.5% recently.
Market Sentiment: LPCN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.00 (+137.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LPCN is in a strong downtrend. The price is approaching resistance at $2.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.5% recently.
Market Sentiment: LPCN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.00 (+137.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.12 -
$2.34
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+8.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.5%)
- BULLISH: Trading 137.2% below Wall St target ($6.00)
- CAUTION: Extended 8.1% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$2.12 -
$2.34
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.01
Resistance Level
$2.37
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.53
Wall Street Target
$6.00
(+137.2%)
Revenue Growth (YoY)
27.2%
Share & Embed Analysis
Last updated: June 24, 2026 4:06 AM ET
Data refreshes hourly during market hours. Next update: 5:06 AM
Data refreshes hourly during market hours. Next update: 5:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LPCN showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
John W Higuchi
BUY
40000 shares
2026-04-07
John W Higuchi
BUY
123000 shares
2026-04-06
Mahesh V Patel
BUY
25000 shares
2026-04-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
